Aurobindo news

Aurobindo Pharma Limited (India) News

Aurobindo Pharma gets US nod for seizure drug

Aurobindo Pharma gets US nod for seizure drug

Reuters India - 3 minutes ago
MUMBAI, Nov 6 (Reuters) - India's Aurobindo Pharma Ltd (ARBN.BO: Quote, Profile, Research) said on Friday it secured final approval from the US Food and Drug Administration for Lamotrigine tablets ...

Aurobindo Pharma gets USFDA nod for epilepsy drug

Aurobindo Pharma gets USFDA nod for epilepsy drug

Myiris.com - 11 minutes ago
Drug maker, Aurobindo Pharma has received the final approval from the US Food and Drug Administration (USFDA) to market Lamotrigine tablets on prescription basis. The said drug would be available ...

Aurobindo Pharma allots 83121 Shares on Conversion of FCCBs

Aurobindo Pharma allots 83121 Shares on Conversion of FCCBs

Equity Bulls - 7 minutes ago
Aurobindo Pharma Ltd has announced that in terms of the issue of USD 60 Million Convertible Bonds due 2010, the Bonds are convertible at any time on or after September 20, 2005 up to August 01 ...

Aurobindo Pharma extends gains on turnaround Q2 results

Aurobindo Pharma extends gains on turnaround Q2 results

India Infoline.com - 56 minutes ago
The stock had risen 0.14% to Rs 750.30 on Tuesday, 3 November 2009 in an otherwise weak market after the company declared its results after market hours on Friday, 30 October 2009. The market was ...

Aurobindo Pharma gains on turnaround Q2 results

Aurobindo Pharma gains on turnaround Q2 results

India Infoline.com - 3 minutes ago
On BSE, 3,196 shares were traded in the counter as against an average daily volume of 35,162 shares in the past one quarter. The stock hit a high of Rs 785 and a low of Rs 755 so far during the ...

Aurobindo Pharma gets nod for two drugs in South Africa

Aurobindo Pharma gets nod for two drugs in South Africa

Stock Watch - 52 minutes ago
Aurobindo Pharma, a leading Hyderabad based drug firm, has secured nod from the South African regulator to manufacture and market two drugs in that country. The company received the permission ...

Syndicate content